312 related articles for article (PubMed ID: 27329522)
1. Glioblastoma: does the pre-treatment geometry matter? A postcontrast T1 MRI-based study.
Pérez-Beteta J; Martínez-González A; Molina D; Amo-Salas M; Luque B; Arregui E; Calvo M; Borrás JM; López C; Claramonte M; Barcia JA; Iglesias L; Avecillas J; Albillo D; Navarro M; Villanueva JM; Paniagua JC; Martino J; Velásquez C; Asenjo B; Benavides M; Herruzo I; Delgado MD; Del Valle A; Falkov A; Schucht P; Arana E; Pérez-Romasanta L; Pérez-García VM
Eur Radiol; 2017 Mar; 27(3):1096-1104. PubMed ID: 27329522
[TBL] [Abstract][Full Text] [Related]
2. Geometrical Measures Obtained from Pretreatment Postcontrast T1 Weighted MRIs Predict Survival Benefits from Bevacizumab in Glioblastoma Patients.
Molina D; Pérez-Beteta J; Martínez-González A; Sepúlveda JM; Peralta S; Gil-Gil MJ; Reynes G; Herrero A; De Las Peñas R; Luque R; Capellades J; Balaña C; Pérez-García VM
PLoS One; 2016; 11(8):e0161484. PubMed ID: 27557121
[TBL] [Abstract][Full Text] [Related]
3. Quantitative volumetric assessment of baseline enhancing tumor volume as an imaging biomarker predicts overall survival in patients with glioblastoma.
Auer TA; Della Seta M; Collettini F; Chapiro J; Zschaeck S; Ghadjar P; Badakhshi H; Florange J; Hamm B; Budach V; Kaul D
Acta Radiol; 2021 Sep; 62(9):1200-1207. PubMed ID: 32938221
[TBL] [Abstract][Full Text] [Related]
4. Radiomic Analysis Reveals Prognostic Information in T1-Weighted Baseline Magnetic Resonance Imaging in Patients With Glioblastoma.
Ingrisch M; Schneider MJ; Nörenberg D; Negrao de Figueiredo G; Maier-Hein K; Suchorska B; Schüller U; Albert N; Brückmann H; Reiser M; Tonn JC; Ertl-Wagner B
Invest Radiol; 2017 Jun; 52(6):360-366. PubMed ID: 28079702
[TBL] [Abstract][Full Text] [Related]
5. A three-dimensional computational analysis of magnetic resonance images characterizes the biological aggressiveness in malignant brain tumours.
Pérez-Beteta J; Martínez-González A; Pérez-García VM
J R Soc Interface; 2018 Dec; 15(149):20180503. PubMed ID: 30958226
[TBL] [Abstract][Full Text] [Related]
6. Morphological MRI-based features provide pretreatment survival prediction in glioblastoma.
Pérez-Beteta J; Molina-García D; Martínez-González A; Henares-Molina A; Amo-Salas M; Luque B; Arregui E; Calvo M; Borrás JM; Martino J; Velásquez C; Meléndez-Asensio B; de Lope ÁR; Moreno R; Barcia JA; Asenjo B; Benavides M; Herruzo I; Lara PC; Cabrera R; Albillo D; Navarro M; Pérez-Romasanta LA; Revert A; Arana E; Pérez-García VM
Eur Radiol; 2019 Apr; 29(4):1968-1977. PubMed ID: 30324390
[TBL] [Abstract][Full Text] [Related]
7. Morphologic Features on MR Imaging Classify Multifocal Glioblastomas in Different Prognostic Groups.
Pérez-Beteta J; Molina-García D; Villena M; Rodríguez MJ; Velásquez C; Martino J; Meléndez-Asensio B; Rodríguez de Lope Á; Morcillo R; Sepúlveda JM; Hernández-Laín A; Ramos A; Barcia JA; Lara PC; Albillo D; Revert A; Arana E; Pérez-García VM
AJNR Am J Neuroradiol; 2019 Apr; 40(4):634-640. PubMed ID: 30923085
[TBL] [Abstract][Full Text] [Related]
8. Algorithmic three-dimensional analysis of tumor shape in MRI improves prognosis of survival in glioblastoma: a multi-institutional study.
Czarnek N; Clark K; Peters KB; Mazurowski MA
J Neurooncol; 2017 Mar; 132(1):55-62. PubMed ID: 28074320
[TBL] [Abstract][Full Text] [Related]
9. Volumetric response quantified using T1 subtraction predicts long-term survival benefit from cabozantinib monotherapy in recurrent glioblastoma.
Ellingson BM; Aftab DT; Schwab GM; Hessel C; Harris RJ; Woodworth DC; Leu K; Chakhoyan A; Raymond C; Drappatz J; de Groot J; Prados MD; Reardon DA; Schiff D; Chamberlain M; Mikkelsen T; Desjardins A; Holland J; Ping J; Weitzman R; Wen PY; Cloughesy TF
Neuro Oncol; 2018 Sep; 20(10):1411-1418. PubMed ID: 29660005
[TBL] [Abstract][Full Text] [Related]
10. Prediction of survival with multi-scale radiomic analysis in glioblastoma patients.
Chaddad A; Sabri S; Niazi T; Abdulkarim B
Med Biol Eng Comput; 2018 Dec; 56(12):2287-2300. PubMed ID: 29915951
[TBL] [Abstract][Full Text] [Related]
11. Multicenter imaging outcomes study of The Cancer Genome Atlas glioblastoma patient cohort: imaging predictors of overall and progression-free survival.
Wangaryattawanich P; Hatami M; Wang J; Thomas G; Flanders A; Kirby J; Wintermark M; Huang ES; Bakhtiari AS; Luedi MM; Hashmi SS; Rubin DL; Chen JY; Hwang SN; Freymann J; Holder CA; Zinn PO; Colen RR
Neuro Oncol; 2015 Nov; 17(11):1525-37. PubMed ID: 26203066
[TBL] [Abstract][Full Text] [Related]
12. Prognostic Value of Dynamic Contrast-Enhanced MRI-Derived Pharmacokinetic Variables in Glioblastoma Patients: Analysis of Contrast-Enhancing Lesions and Non-Enhancing T2 High-Signal Intensity Lesions.
Kang Y; Hong EK; Rhim JH; Yoo RE; Kang KM; Yun TJ; Kim JH; Sohn CH; Park SW; Choi SH
Korean J Radiol; 2020 Jun; 21(6):707-716. PubMed ID: 32410409
[TBL] [Abstract][Full Text] [Related]
13. Recurrent glioblastoma treated with bevacizumab: contrast-enhanced T1-weighted subtraction maps improve tumor delineation and aid prediction of survival in a multicenter clinical trial.
Ellingson BM; Kim HJ; Woodworth DC; Pope WB; Cloughesy JN; Harris RJ; Lai A; Nghiemphu PL; Cloughesy TF
Radiology; 2014 Apr; 271(1):200-10. PubMed ID: 24475840
[TBL] [Abstract][Full Text] [Related]
14. Volume of high-risk intratumoral subregions at multi-parametric MR imaging predicts overall survival and complements molecular analysis of glioblastoma.
Cui Y; Ren S; Tha KK; Wu J; Shirato H; Li R
Eur Radiol; 2017 Sep; 27(9):3583-3592. PubMed ID: 28168370
[TBL] [Abstract][Full Text] [Related]
15. Determining a cut-off residual tumor volume threshold for patients with newly diagnosed glioblastoma treated with temozolomide chemoradiotherapy: A multicenter cohort study.
Woo PYM; Ho JMK; Tse TPK; Lam SW; Mak CHK; Chan DTM; Lee MWY; Wong ST; Chan KY; Poon WS
J Clin Neurosci; 2019 May; 63():134-141. PubMed ID: 30712777
[TBL] [Abstract][Full Text] [Related]
16. Multi-parametric and multi-regional histogram analysis of MRI: modality integration reveals imaging phenotypes of glioblastoma.
Li C; Wang S; Serra A; Torheim T; Yan JL; Boonzaier NR; Huang Y; Matys T; McLean MA; Markowetz F; Price SJ
Eur Radiol; 2019 Sep; 29(9):4718-4729. PubMed ID: 30707277
[TBL] [Abstract][Full Text] [Related]
17. Tumor Surface Regularity at MR Imaging Predicts Survival and Response to Surgery in Patients with Glioblastoma.
Pérez-Beteta J; Molina-García D; Ortiz-Alhambra JA; Fernández-Romero A; Luque B; Arregui E; Calvo M; Borrás JM; Meléndez B; Rodríguez de Lope Á; Moreno de la Presa R; Iglesias Bayo L; Barcia JA; Martino J; Velásquez C; Asenjo B; Benavides M; Herruzo I; Revert A; Arana E; Pérez-García VM
Radiology; 2018 Jul; 288(1):218-225. PubMed ID: 29924716
[TBL] [Abstract][Full Text] [Related]
18. Automated Volumetric Analysis of Postoperative Magnetic Resonance Imaging Predicts Survival in Patients with Glioblastoma.
Krivoshapkin AL; Sergeev GS; Gaytan AS; Kalneus LE; Kurbatov VP; Abdullaev OA; Salim N; Bulanov DV; Simonovich AE
World Neurosurg; 2019 Jun; 126():e1510-e1517. PubMed ID: 30910753
[TBL] [Abstract][Full Text] [Related]
19. Rapid Early Tumor Progression is Prognostic in Glioblastoma Patients.
Palmer JD; Bhamidipati D; Shukla G; Sharma D; Glass J; Kim L; Evans JJ; Judy K; Farrell C; Andrews DW; Wang ZW; Peiper SC; Werner-Wasik M; Shi W
Am J Clin Oncol; 2019 May; 42(5):481-486. PubMed ID: 30973372
[TBL] [Abstract][Full Text] [Related]
20. Prognostic value of contrast enhancement and FLAIR for survival in newly diagnosed glioblastoma treated with and without bevacizumab: results from ACRIN 6686.
Boxerman JL; Zhang Z; Safriel Y; Rogg JM; Wolf RL; Mohan S; Marques H; Sorensen AG; Gilbert MR; Barboriak DP
Neuro Oncol; 2018 Sep; 20(10):1400-1410. PubMed ID: 29590461
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
